Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 4/20 | 0.42 |
| ▸ | HTR7 | P34969 | 3/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | MAP3K8 | P41279 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20575148 | 0.84 | HTR7 (0.53) | PRCPHTR7JAK2JAK3 | |
| SCHEMBL20575147 | 0.84 | HTR7 (0.53) | PRCPHTR7JAK2JAK3 | |
| SCHEMBL23780468 | 0.78 | PRCP (0.45) | PRCPHTR7JAK2JAK3 | |
| SCHEMBL21593091 | 0.78 | HTR7 (0.58) | PRCPHTR7JAK2JAK3 | |
| SCHEMBL4375466 | 0.78 | HTR7 (0.58) | PRCPHTR7JAK2JAK3 | |
| SCHEMBL4375461 | 0.78 | HTR7 (0.58) | PRCPHTR7JAK2JAK3 | |
| SCHEMBL20575175 | 0.78 | SCN1A (0.47) | HTR7 | |
| SCHEMBL20575315 | 0.77 | SCN1A (0.39) | PRCPHTR7MAP3K8 | |
| SCHEMBL23291891 | 0.75 | EGFR (0.45) | PRCPHTR7FAAHJAK2JAK3 | |
| SCHEMBL20575318 | 0.75 | HDAC6 (0.43) | HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800760-B2 | Trk inhibition | NANTBIO, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10800760-B2 | Trk inhibition | NANTBIO, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20180346450-A1 | TRK INHIBITION | NANTBIO, INC. | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346450-A1 | TRK INHIBITION | NTRK1, NTRK3, NTRK2 | PRCP 3497/4885HTR7 2187/4885CSF1R 100/4885 |
| US-10800760-B2 | Trk inhibition | NTRK1, NTRK3, NTRK2 | PRCP 3497/4885HTR7 2187/4885CSF1R 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.